Regenerx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (the "Company" or "RegeneRx") announced today that it is collaborating with the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) and Dr. Gabriel Sosne, Associate Professor of Ophthalmology at Wayne State University, to evaluate Tí˛4"s (RGN-259 eye drops) ability to prevent or reduce damage to the eye caused by exposure to chemical agents. The ability to prevent or reduce such damage is the focus of substantial efforts by both the military and homeland security. The project will consist of a series of research experiments over the next twelve months with Tí˛4, which is being commercially developed by RegeneRx and is in Phase II clinical trials.